Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 142, Issue 6, pp 1387–1394 | Cite as

Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan

  • Takamichi ItoEmail author
  • Hiroshi Uchi
  • Takeshi Nakahara
  • Gaku Tsuji
  • Yoshinao Oda
  • Akihito Hagihara
  • Masutaka Furue
Original Article – Clinical Oncology

Abstract

Purpose

For a better understanding of angiosarcoma, we summarized our 30-year experience of conventional treatment outcomes before the era of molecular-targeted therapy.

Methods

We conducted a retrospective review of our 43 patients with cutaneous angiosarcoma of the head and face, and investigated the prognostic factors including the treatment strategy. Disease-specific survival (DSS) and event-free survival (EFS) were estimated using the Kaplan–Meier method, together with multivariate analyses using the Cox proportional hazard regression model.

Results

All patients were Japanese (25 males and 18 females), with a mean age of 72.1. For the initial treatment of the primary lesion, 34 patients underwent radiotherapy with or without taxanes (docetaxel and/or paclitaxel); only 6 patients underwent surgical excision. As the systemic adjuvant therapy, 19 patients were treated with taxanes and 15 with interleukin-2. Interestingly, patients who underwent the continued chemotherapy with taxanes had significantly prolonged DSS (5-year DSS, 57.0 vs. 19.6 %; median survival, 62.2 vs. 17.7 months; P = 0.0049) and EFS (5-year EFS, 34.9 vs. 5.6 %; median survival, 46.7 vs. 12.4 months; P = 0.0024) than the others. The continuous use of taxanes was also a prognostic factor in multivariate analyses. Neither radiotherapy nor surgical excision significantly influenced the patients’ outcome. Among five patients who survived more than 5 years, three underwent surgical excision of the primary tumor or lung metastasis.

Conclusions

Our results suggest that continued chemotherapy with taxanes is important for patient survival.

Keywords

Angiosarcoma Skin Prognostic factor Taxane Treatment Pazopanib 

Notes

Acknowledgments

The authors thank all of the patients and the members of our laboratory. This work was partly supported by Grants from the Ministry of Health, Labor and Welfare, the Research on Development of New Drugs from Japan Agency for Medical Research and Development (AMED), and the Leading Advanced Projects for Medical Innovation (LEAP).

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. This article does not contain any studies with animals performed by any of the authors.

Supplementary material

432_2016_2151_MOESM1_ESM.eps (87 kb)
Supplementary material 1 (EPS 86 kb)
432_2016_2151_MOESM2_ESM.eps (85 kb)
Supplementary material 2 (EPS 84 kb)
432_2016_2151_MOESM3_ESM.eps (133 kb)
Supplementary material 3 (EPS 133 kb)
432_2016_2151_MOESM4_ESM.eps (131 kb)
Supplementary material 4 (EPS 131 kb)
432_2016_2151_MOESM5_ESM.eps (134 kb)
Supplementary material 5 (EPS 133 kb)
432_2016_2151_MOESM6_ESM.eps (132 kb)
Supplementary material 6 (EPS 131 kb)
432_2016_2151_MOESM7_ESM.docx (12 kb)
Supplementary material 7 (DOCX 11 kb)

References

  1. Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, DeLaney TF, Yoon SS (2007) Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 14:1953–1967CrossRefPubMedGoogle Scholar
  2. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS (2013) An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24:257–263CrossRefPubMedGoogle Scholar
  3. Albores-Saavedra J, Schwartz AM, Henson DE, Kostun L, Hart A, Angeles-Albores D, Chablé-Montero F, Cutaneous angiosarcoma (2011) Analysis of 434 cases from the surveillance, epidemiology, and end results program, 1973–2007. Ann Diagn Pathol 15:93–97CrossRefPubMedGoogle Scholar
  4. Aust MR, Olsen KD, Lewis JE, Nascimento AG, Meland NB, Foote RL, Suman VJ (1997) Angiosarcomas of the head and neck: clinical and pathologic characteristics. Ann Otol Rhinol Laryngol 106:943–951CrossRefPubMedGoogle Scholar
  5. Buschmann A, Lehnhardt M, Toman N, Preiler P, Salakdeh MS, Muehlberger T (2008) Surgical treatment of angiosarcoma of the scalp: less is more. Ann Plast Surg 61:399–403CrossRefPubMedGoogle Scholar
  6. Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  7. Espat NJ, Lewis JJ, Woodruff JM, Antonescu C, Xia J, Leung D, Brennan MF (2000) Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma 4:173–177CrossRefPubMedPubMedCentralGoogle Scholar
  8. Fata F, O’Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86:2034–2037CrossRefPubMedGoogle Scholar
  9. Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, Ranchère D, Pouillart P, Coindre JM, Blay JY (2007) Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 18:2030–2036CrossRefPubMedGoogle Scholar
  10. Fujisawa Y, Yoshino K, Kadono T, Miyagawa T, Nakamura Y, Fujimoto M (2014) Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. Br J Dermatol 171:1493–1500CrossRefPubMedGoogle Scholar
  11. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG (2005) A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11:241–247CrossRefPubMedGoogle Scholar
  12. Goldblum JR, Weiss SW, Folpe AL (2014) Enzinger and Weiss’s soft tissue tumors, 6th edn. Elsevier, PhiladelphiaGoogle Scholar
  13. Gründahl JE, Hallermann C, Schulze HJ, Klein M, Wermker K (2015) Cutaneous angiosarcoma of head and neck: a new predictive score for locoregional metastasis. Transl Oncol 8:169–175CrossRefPubMedPubMedCentralGoogle Scholar
  14. Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM (2011) Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 33:661–667CrossRefPubMedPubMedCentralGoogle Scholar
  15. Hodgkinson DJ, Soule EH, Woods JE (1979) Cutaneous angiosarcoma of the head and neck. Cancer 44:1106–1113CrossRefPubMedGoogle Scholar
  16. Holden CA, Spittle MF, Jones EW (1987) Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 59:1046–1057CrossRefPubMedGoogle Scholar
  17. Ito T, Kaku Y, Nagae K, Nakano-Nakamura M, Nakahara T, Oda Y, Hagihara A, Furue M, Uchi H (2015a) Tumor thickness as a prognostic factor in extramammary Paget’s disease. J Dermatol 42:269–275CrossRefPubMedGoogle Scholar
  18. Ito T, Wada M, Nagae K, Nakano-Nakamura M, Nakahara T, Hagihara A, Furue M, Uchi H (2015b) Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? J Am Acad Dermatol 72:71–77CrossRefPubMedGoogle Scholar
  19. Ito T, Wada M, Nagae K, Nakano-Nakamura M, Nakahara T, Hagihara A, Furue M, Uchi H (2015c) Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma. J Eur Acad Dermatol Venereol 29:912–918CrossRefPubMedGoogle Scholar
  20. Köhler HF, Neves RI, Brechtbühl ER, Mattos Granja NV, Ikeda MK, Kowalski LP (2008) Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution. Otolaryngol Head Neck Surg 139:519–524CrossRefPubMedGoogle Scholar
  21. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, Lazar AJ, Lev D (2010) Angiosarcoma: clinical and molecular insights. Ann Surg 251:1098–1106CrossRefPubMedGoogle Scholar
  22. Letsa I, Benson C, Al-Muderis O, Judson I (2014) Angiosarcoma of the face and scalp: effective systemic treatment in the older patient. J Geriatr Oncol 5:276–280CrossRefPubMedGoogle Scholar
  23. Lydiatt WM, Shaha AR, Shah JP (1994) Angiosarcoma of the head and neck. Am J Surg 168:451–454CrossRefPubMedGoogle Scholar
  24. Maddox JC, Evans HL (1981) Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer 48:1907–1921CrossRefPubMedGoogle Scholar
  25. Mark RJ, Poen JC, Tran LM, Fu YS, Angiosarcoma Juillard GF (1996) A report of 67 patients and a review of the literature. Cancer 77:2400–2406CrossRefPubMedGoogle Scholar
  26. Mendenhall WM, Mendenhall CM, Werning JW, Reith JD, Mendenhall NP (2006) Cutaneous angiosarcoma. Am J Clin Oncol 29:524–528CrossRefPubMedGoogle Scholar
  27. Miki Y, Tada T, Kamo R, Hosono MN, Tamiya H, Shimatani Y, Tsutsumi S, Ogino R, Miki Y (2013) Single institutional experience of the treatment of angiosarcoma of the face and scalp. Br J Radiol 86:20130439CrossRefPubMedPubMedCentralGoogle Scholar
  28. Morgan MB, Swann M, Somach S, Eng W, Smoller B (2004) Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 50:867–874CrossRefPubMedGoogle Scholar
  29. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C (2007) Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 110:648–651CrossRefPubMedGoogle Scholar
  30. Ohguri T, Imada H, Nomoto S, Yahara K, Hisaoka M, Hashimoto H, Tokura Y, Nakamura K, Shioyama Y, Honda H, Terashima H, Moroi Y, Furue M, Korogi Y (2005) Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys 61:1446–1453CrossRefPubMedGoogle Scholar
  31. Patel SH, Hayden RE, Hinni ML, Wong WW, Foote RL, Milani S, Wu Q, Ko SJ, Halyard MY (2015) Angiosarcoma of the scalp and face: the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg 141:335–340CrossRefPubMedGoogle Scholar
  32. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, Rees R, Sondak VK (2003) Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 98:1716–1726CrossRefPubMedGoogle Scholar
  33. Perez MC, Padhya TA, Messina JL, Jackson RS, Gonzalez RJ, Bui MM, Letson GD, Cruse CW, Lavey RS, Cheong D, Forster MR, Fulp WJ, Sondak VK, Zager JS (2013) Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 20:3391–3397CrossRefPubMedPubMedCentralGoogle Scholar
  34. Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N, French Sarcoma Group (GSF/GETO) (2012) Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 17:260–266CrossRefPubMedPubMedCentralGoogle Scholar
  35. Sleijfer S (2012) Phase II studies in soft tissue sarcoma: time for reappraisal. Oncologist 17:154–156CrossRefPubMedPubMedCentralGoogle Scholar
  36. Ward JR, Feigenberg SJ, Mendenhall NP, Marcus RB Jr, Mendenhall WM (2003) Radiation therapy for angiosarcoma. Head Neck 25:873–878CrossRefPubMedGoogle Scholar
  37. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ (2010) Angiosarcoma. Lancet Oncol 11:983–991CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Takamichi Ito
    • 1
    • 2
    Email author
  • Hiroshi Uchi
    • 1
  • Takeshi Nakahara
    • 1
    • 3
  • Gaku Tsuji
    • 1
  • Yoshinao Oda
    • 2
  • Akihito Hagihara
    • 4
  • Masutaka Furue
    • 1
  1. 1.Department of Dermatology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Anatomic Pathology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  3. 3.Division of Skin Surface Sensing, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  4. 4.Department of Health Services Management and Policy, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations